Talks, James

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier, J. S., Khanani, A. M., Quezada Ruiz, C., Basu, K., Ferrone, P. J., Brittain, C., Figueroa, M. S., Lin, H., Holz, F. G., Patel, V., et al. (2022) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 785

Defining response to anti-VEGF therapies in neovascular AMD

Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 355

Stakeholder Perspectives of Clinical Artificial Intelligence Implementation: Systematic Review of Qualitative Evidence

Hogg, H. D. J., Al-Zubaidy, M., Technology Enhanced Macular Services Study Reference Group, Talks, J., Denniston, A. K., Kelly, C. J., Malawana, J., Papoutsi, C., Teare, M. D., Keane, P. A., et al. (2023) · Journal of Medical Internet Research

Artificial Intelligence in Healthcare and EducationHealth Policy Implementation Science

Cited by 163

Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK aflibercept users group

Almuhtaseb, H., Johnston, R. L., Talks, J. S., & Lotery, A. J. (2017) · Eye

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 33

Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis

Sivaprasad, S., Bailey, C., Downey, L., Gilbert, R., Gale, R., Kotagiri, A., Mahmood, S., Morgan-Warren, P., Napier, J., Narendran, N., et al. (2024) · Current Medical Research and Opinion

Health Systems, Economic Evaluations, Quality of LifeRetinal Diseases and Treatments

Cited by 15